Sponsor or institution

Clinical trials and research at Sinocelltech Ltd.

• 14Clinical trials
• 2Countries

Newest trials

All recruiting trials (14)

• SCTB41 plus chemotherapy vs tislelizumab plus chemotherapy as first-line treatment for advanced NSCLC

  This trial tests SCTB41 plus chemotherapy to see if it helps people with advanced NSCLC more than tislelizumab plus chemotherapy.

  Recruiting Phase 2/3 Sinocelltech Ltd. · Guangzhou, Guangdong · NCT07662395

• SCTB35 with Gemcitabine and Oxaliplatin in relapsed or refractory DLBCL

  This trial tests whether SCTB35 added to gemcitabine and oxaliplatin helps people with relapsed or refractory diffuse large B-cell lymphoma stay disease-free longer compared with rituximab plus gemcitabine and oxaliplatin.

  Recruiting Phase 3 Sinocelltech Ltd. · Beijing · NCT07570823

• SCTB35 plus Lenalidomide for relapsed or refractory follicular lymphoma

  This trial tests whether SCTB35 given with Lenalidomide can help people whose follicular lymphoma has come back or stopped responding to prior treatment.

  Recruiting Phase 3 Sinocelltech Ltd. · Beijing, Beijing Municipality · NCT07562022

• SCT800 for preventing and treating bleeds in previously untreated severe hemophilia A patients

  This test tries SCT800, a recombinant factor VIII, as regular prevention and to treat bleeds in male patients with severe hemophilia A who haven't had prior factor VIII treatment.

  Recruiting Phase 3 Sinocelltech Ltd. · Beijing, Beijing Municipality · NCT07437404

• SCTC21C plus bortezomib, cyclophosphamide and dexamethasone for newly diagnosed systemic light-chain (AL) amyloidosis

  This trial tests whether adding SCTC21C to standard bortezomib‑cyclophosphamide‑dexamethasone (VCd) helps people with newly diagnosed AL (light‑chain) amyloidosis achieve better hematologic responses and outcomes.

  Recruiting Phase 3 Sinocelltech Ltd. · Beijing, Beijing Municipality · NCT07388602

• SCTB14 as first-line therapy for advanced NSCLC

  This trial will test whether SCTB14 works better than pembrolizumab as first treatment for adults with unresectable locally advanced or metastatic, driver-gene–negative NSCLC whose tumors have PD-L1 TPS ≥10%.

  Recruiting Phase 3 Sinocelltech Ltd. · Shanghai, Shanghai Municipality · NCT07362459

• Adding SCTC21C to standard bortezomib–lenalidomide–dexamethasone (VRd) for newly diagnosed multiple myeloma patients not eligible for transplant.

  This trial will test whether adding the experimental drug SCTC21C to the standard bortezomib–lenalidomide–dexamethasone (VRd) regimen helps people with newly diagnosed multiple myeloma who are not eligible for transplant live longer without disease progression and reach deeper remissions.

  Recruiting Phase 3 Sinocelltech Ltd. · Beijing, Beijing Municipality · NCT07297329

• SCT650C for adults with moderate to severe hidradenitis suppurativa

  This trial will test whether subcutaneous injections of SCT650C help adults with moderate to severe hidradenitis suppurativa by reducing inflammatory lesions and symptoms.

  Recruiting Phase 2 Sinocelltech Ltd. · Samsun, Turkey · NCT07244510

• SCTB39-1 for adults with advanced solid tumors (Phase 1/2 dose-escalation and expansion)

  This trial will try SCTB39-1 in adults with advanced malignant solid tumors to see if it is safe and can shrink or slow tumors.

  Recruiting Phase 1/2 Sinocelltech Ltd. · Beijing · NCT07050641

• Evaluating SCTB35 for treating systemic lupus erythematosus

  This study is testing a new treatment called SCTB35 to see if it is safe and effective for people with systemic lupus erythematosus.

  Recruiting Phase 1/2 Sinocelltech Ltd. · Beijing and 13 other locations · NCT06841042

• Evaluating a new vaccine for Respiratory Syncytial Virus

  This study is testing a new vaccine for Respiratory Syncytial Virus (RSV) in adults to see how safe it is and how well it helps the immune system.

  Recruiting Phase 1/2 Sinocelltech Ltd. · Langfang, Hebei and 1 other locations · NCT06754605

• SCT520FF treatment for neovascular (wet) age-related macular degeneration

  This study will test whether injections of SCT520FF are safe and help people aged 45–80 with neovascular (wet) age-related macular degeneration.

  Recruiting Phase 1/2 Sinocelltech Ltd. · Tianjing · NCT06672536

• Exploring SCTB41 for advanced malignant solid tumors

  This study is testing a new treatment called SCTB41 to see if it is safe and effective for adults with advanced solid tumors.

  Recruiting Phase 1/2 Sinocelltech Ltd. · Guangzhou, Guangdong · NCT06600022

• Evaluating SCTC21C for patients with CD38+ blood cancers

  This study is testing a new treatment called SCTC21C to see if it can help people with certain types of blood cancers that have come back or didn’t respond to other treatments.

  Recruiting Phase 1 Sinocelltech Ltd. · Beijing, Beijing Municipality · NCT06252298

Quick answers

How many clinical trials run by Sinocelltech Ltd. are recruiting right now?

14, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 2 countries. The most sites are in China (13 trials), Turkey (Türkiye) (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 3: 6, Phase 1/2: 5, Phase 2/3: 1, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →